WuXi AppTec Co., Ltd. (HKG:2359)

Market Cap	297.83B
Revenue (ttm)	47.96B
Net Income (ttm)	16.39B
Shares Out	n/a
EPS (ttm)	5.09
PE Ratio	18.18
Forward PE	17.73
Dividend	1.82 (1.76%)
Ex-Dividend Date	Sep 8, 2025

Volume	5,121,912
Average Volume	5,513,781
Open	102.30
Previous Close	102.30
Day's Range	102.30 - 106.10
52-Week Range	44.30 - 124.70
Beta	0.82
RSI	37.17
Earnings Date	Mar 16, 2026

About WuXi AppTec

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecula...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2000
• Employees: 39,414
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2359

Financial Performance

In 2024, WuXi AppTec's revenue was 37.92 billion, a decrease of -1.97% compared to the previous year's 38.68 billion. Earnings were 9.45 billion, a decrease of -1.63%.

Financial numbers in CNY